PT  - JOURNAL ARTICLE
AU  - Yuan, Jinyun
AU  - Xu, Lu
AU  - Chien, Chih-Yen
AU  - Yang, Yaoheng
AU  - Yue, Yimei
AU  - Fadera, Siaka
AU  - Stark, Andrew H.
AU  - Schwetye, Katherine E.
AU  - Nazeri, Arash
AU  - Desai, Rupen
AU  - Athiraman, Umeshkumar
AU  - Chaudhuri, Aadel A.
AU  - Chen, Hong
AU  - Leuthardt, Eric C.
TI  - First-in-human prospective trial of sonobiopsy in glioblastoma patients using neuronavigation-guided focused ultrasound
AID  - 10.1101/2023.03.17.23287378
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.03.17.23287378
4099  - http://medrxiv.org/content/early/2023/03/18/2023.03.17.23287378.short
4100  - http://medrxiv.org/content/early/2023/03/18/2023.03.17.23287378.full
AB  - Sonobiopsy is an emerging technology that combines focused ultrasound (FUS) with microbubbles to enrich circulating brain disease-specific biomarkers for noninvasive molecular diagnosis of brain diseases. Here, we report the first-in-human prospective trial of sonobiopsy in glioblastoma patients to evaluate its feasibility and safety in enriching circulating tumor biomarkers. A nimble FUS device integrated with a clinical neuronavigation system was used to perform sonobiopsy following an established clinical workflow for neuronavigation. Analysis of blood samples collected before and after FUS sonication showed enhanced plasma circulating tumor biomarker levels. Histological analysis of surgically resected tumors confirmed the safety of the procedure. Transcriptome analysis of sonicated and unsonicated tumor tissues found that FUS sonication modulated cell physical structure-related genes but evoked minimal inflammatory response. These feasibility and safety data support the continued investigation of sonobiopsy for noninvasive molecular diagnosis of brain diseases.Competing Interest StatementECL and HC have a patent on the sonobiopsy technique (US20190323086A1).Clinical TrialNCT0528173Funding StatementThis work was supported by the National Institutes of Health R01CA276174, R01MH116981, UG3MH126861, R01EB027223, and R01EB030102.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Research Ethics Board at Washington University in St. Louis, School of Medicine, and was registered with ClinicalTrials.gov (NCT0528173).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data that support the findings of this study are available from the corresponding authors upon reasonable request.